Danica Grujic Selected Research

oxalate decarboxylase

1/2016	A Double-Blind, Placebo Controlled, Randomized Phase 1 Cross-Over Study with ALLN-177, an Orally Administered Oxalate Degrading Enzyme.
1/2009	Hyperoxaluria is reduced and nephrocalcinosis prevented with an oxalate-degrading enzyme in mice with hyperoxaluria.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Danica Grujic Research Topics

Disease

4	Hyperoxaluria (Oxaluria) 01/2021 - 01/2009
3	Chronic Renal Insufficiency 01/2020 - 01/2016
2	Gout 01/2020 - 01/2017
2	Hyperuricemia 01/2020 - 01/2017
2	Cystic Fibrosis (Mucoviscidosis) 10/2018 - 01/2017
1	Exocrine Pancreatic Insufficiency 10/2018
1	Nephrolithiasis 01/2016
1	Body Weight (Weight, Body) 12/2014
1	Urolithiasis 01/2009
1	Nephrocalcinosis 01/2009

Drug/Important Bio-Agent (IBA)

3	reloxaliaseIBA 01/2021 - 01/2016
3	OxalatesIBA 04/2019 - 01/2009
2	Urate Oxidase (Uricase)IBA 01/2020 - 01/2017
2	Uric Acid (Urate)IBA 01/2020 - 01/2017
2	oxalate decarboxylaseIBA 01/2016 - 01/2009
2	EnzymesIBA 01/2016 - 01/2009
1	Xanthine OxidaseIBA 01/2020
1	FatsIBA 10/2018
1	CalciumIBA 01/2016
1	Amylases FDA Link 12/2014
1	Peptide Hydrolases (Proteases)FDA Link 12/2014
1	Ethylene Glycol (Monoethylene Glycol)IBA 01/2009
1	Calcium OxalateIBA 01/2009

Therapy/Procedure

3	Therapeutics 01/2020 - 01/2009
2	Enzyme Therapy 01/2020 - 04/2019
2	Enteral Nutrition (Feeding, Tube) 10/2018 - 01/2017
1	Injections 01/2017